Definium Therapeutics Inc (DFTX) Jefferies Global Healthcare Conference 2025 summary

Regulatory and industry landscape

• Regulatory environment is evolving, with increased engagement from FDA and global regulators, highlighted by Breakthrough Therapy designation for the lead program.

• Psychiatry is experiencing a paradigm shift as providers express strong interest in adopting new psychedelic-based treatments for anxiety and depression.

• Current treatment models are seen as inadequate, with a growing demand for transformative therapies that go beyond symptom suppression.

• Infrastructure for interventional psychiatry is expanding, with clinics preparing to deliver new therapies upon approval.

• The field is moving away from historical practices, focusing on evidence-based approaches and broad patient access.

Clinical development and trial progress

• Lead program MM120, an orally dissolving tablet formulation of LSD, is in phase III trials for generalized anxiety disorder (GAD) and major depressive disorder (MDD), with data readouts expected in 2026.

• Phase II data showed rapid, durable efficacy, with 48% of GAD patients in remission at 12 weeks and effect sizes more than double standard of care.

• Ongoing phase III studies include two in GAD (Voyage and Panorama) and one in MDD (Emerge), all featuring 12-week primary endpoints and 40-week extension periods for real-world assessment.

• The adverse event profile is limited to transient, mild-to-moderate effects on dosing day, with no significant long-term safety concerns observed.

• Study designs maximize flexibility and integrity, including secondary controls and open-label extensions to assess durability and retreatment needs.

Patient experience and therapeutic impact

• MM120 induces perceptual and cognitive changes, often described as illusions rather than true hallucinations, due to altered sensory processing.

• Patients typically report a reorientation to their disorder, with many describing a new relationship to anxiety or depression after treatment.

• The in-clinic experience is generally calm, with patients resting under observation for eight hours and minimal intervention required.

• Most patients find the experience pleasant and would repeat it if needed, though some challenging experiences can occur, as with any therapy.

• The therapy is positioned as autotherapeutic, not requiring adjunctive psychotherapy during administration.